CD40 and neoplasm: Because both PPARγ and PPARδ inhibitors were reported to inhibit tumor-induced M2 macrophage polarization17–20, the different effects of PPARγ vs. PPARδ inhibitors to enhance immunotherapy with anti-CD40 mAb suggest that tumor-associated macrophages (TAMs) were not the targeting cells as we initially hypothesized.